Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Dividend AI-generated analysis

📈 BMY raised its quarterly dividend to $0.63 per share, marking the 17th consecutive annual increase and the 94th year of payments.

💰 The company reported second-quarter EPS of $2.04, beating the $1.597 estimate, and raised 2026 non-GAAP EPS guidance to $6.75-$7.00.

🛡️ Total debt stands at approximately $43.1 billion, with the company paying down $1.2 billion in the most recent quarter.

⚠️ Eliquis sales are expected to decline by $1.5 billion to $2 billion by 2027 due to generic competition and patent expiry in April 2028.

🔬 The replacement drug milvexian has delayed its atrial fibrillation trial data until the first quarter of 2027, creating uncertainty for future revenue replacement.

📈 Growth Portfolio sales surged 15% to $7.56 billion in Q2, driven by Camzyos (+60%), Breyanzi (+41%), and Reblozyl (+29%).

📉 Older drugs face significant headwinds, with Revlimid sales falling 49% and Pomalyst dropping 71% year-over-year.

💵 Operating cash flow reached approximately $3.4 billion for the quarter, supporting a dividend that uses only 36-37% of guided earnings.

📊 Shares have risen 45% over the past year and 17.26% year-to-date, reflecting investor confidence in the company's growth strategy.

Bullish Signals
  • Bristol Myers Squibb raised its quarterly dividend to $0.63 per share for the 17th consecutive year, with a payout ratio of only 36-37% against raised 2026 EPS guidance.
  • Second-quarter earnings beat estimates at $2.04 EPS, and management increased full-year non-GAAP EPS guidance to $6.75-$7.00, signaling strong operational performance.
  • The Growth Portfolio delivered robust 15% sales growth in Q2, reaching $7.56 billion, with standout performers Camzyos (+60%) and Breyanzi (+41%).
  • Strong operating cash flow of approximately $3.4 billion per quarter provides ample liquidity to fund the dividend and reduce the $43.1 billion debt load.
  • The company successfully paid down $1.2 billion in debt during the quarter, demonstrating a disciplined balance sheet management strategy.
Risk Factors
  • Eliquis is projected to lose $1.5 billion to $2 billion in sales by 2027 due to generic competition and patent expiry in April 2028.
  • The critical replacement drug milvexian has delayed its atrial fibrillation trial data until Q1 2027, introducing timing risk for revenue replacement.
  • Older blockbuster drugs are shrinking rapidly, with Revlimid sales falling 49% and Pomalyst dropping 71% year-over-year in the second quarter.
  • The company carries a substantial $43.1 billion debt load, which limits its ability to accelerate dividend increases compared to peers like Pfizer.
Full Analysis
Bristol Myers Squibb (BMY) maintains a 4.2% dividend yield supported by 17 consecutive annual increases and 94 years of payments, though recent growth faces headwinds from patent expirations and significant debt levels. The company reported second-quarter EPS of $2.04, exceeding analyst estimates, and raised its 2026 non-GAAP EPS guidance to $6.75-$7.00. Management highlighted that the current dividend consumes approximately 36% to 37% of guided earnings, providing a comfortable cushion for future payouts while allowing for debt reduction. The core challenge for BMY's dividend trajectory lies in the impending loss of sales from its blockbuster drug Eliquis, which is projected to decline by $1.5 billion to $2 billion by 2027 due to generic competition following its patent expiry in April 2028. The company is relying on milvexian to replace Eliquis revenue, but the drug's atrial fibrillation trial data has been delayed until the first quarter of 2027. Additionally, BMY carries approximately $43.1 billion in total debt, which constrains its ability to accelerate dividend raises compared to peers. Despite these risks, BMY demonstrates resilience through strong performance in its Growth Portfolio, where sales rose 15% to $7.56 billion in the second quarter. Key growth drivers include Camzyos (up 60%), Breyanzi (up 41%), and Reblozyl (up 29%), which are offsetting steep declines in older drugs like Revlimid, which fell 49%. The stock has gained 45% over the past year, pushing the yield down slightly, but analysts view the payout as safe given the company's robust cash flow of roughly $3.4 billion per quarter and its commitment to returning capital to shareholders.